# Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

> **NCT02468193** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Cushing's Syndrome
- Ectopic Corticotropin Syndrome
- Adrenal Adenoma
- Adrenal Carcinoma
- AIMAH
- PPNAD

## Interventions

- **DRUG:** Osilodrostat

## Key facts

- **NCT ID:** NCT02468193
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-24
- **Primary completion:** 2018-06-07
- **Final completion:** 2018-10-29
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468193, "Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02468193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*